Argenx's Vyvgart Offers a Substantial Advance Over Other Treatments for Generalized Myasthenia Gravis, Spherix Survey Suggests
/PRNewswire/ -- At the end of last year, argenxs Vyvgart (efgartigimod alfa-fcab) was approved by the FDA for the treatment of generalized myasthenia gravis...
Roche Genentech Roche Genentech Ocrevus Vyvgart Argenx Ultomiris Astrazeneca Astrazeneca Ultomiris Our Services
Source: prnewswire.com